INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,793,000 | -62.9% | 38,536 | -54.5% | 0.01% | -60.9% |
| Q2 2022 | $4,836,000 | -25.2% | 84,720 | -19.9% | 0.02% | +9.5% |
| Q1 2022 | $6,469,000 | +1947.2% | 105,728 | +428.6% | 0.02% | +2000.0% |
| Q3 2017 | $316,000 | +96.3% | 20,000 | +53.8% | 0.00% | 0.0% |
| Q2 2017 | $161,000 | -20.3% | 13,000 | +150.0% | 0.00% | 0.0% |
| Q2 2016 | $202,000 | -24.6% | 5,200 | -22.4% | 0.00% | 0.0% |
| Q3 2015 | $268,000 | -74.2% | 6,700 | -79.4% | 0.00% | -80.0% |
| Q2 2015 | $1,037,000 | -73.6% | 32,450 | -80.3% | 0.01% | -72.2% |
| Q1 2015 | $3,935,000 | – | 164,797 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |